

**VANCOUVER HOSPITAL & HEALTH SCIENCES CENTRE
PHARMACY SERVICES
NON-FORMULARY DRUG DATA SHEET**

DRUG NAME

Ancestim

ALTERNATE NAME

Stemgen™
r-metHuSCF
Recombinant-methionyl human stem cell factor

MANUFACTURER

Amgen

STRENGTH

Ancestim 1875 mcg vial
(company supplied 1.2ml SWFI)

DOSAGE FORM

lyophilized powder for reconstitution

INDICATIONS

- Used in combination with filgrastim (GCSF) to provide a sustained increase in the number of peripheral blood progenitor cells (PBPC) capable of engraftment, to increase the proportion of patients reaching a PBPC target and to reduce the number of aphereses required to collect a target number of PBPC.
- For mobilization of progenitor cells from bone marrow to the peripheral blood in combination with GCSF, with or without PBPC-mobilizing chemotherapy.

DOSAGE AND ADMINISTRATION (SEE PRODUCT MONOGRAPH FOR COMPLETE DOSING INSTRUCTIONS)

- 20 mcg/kg/day SC daily
- **NOT** to be given IV
- Ancestim should not be given without GCSF, but must be administered as separate injections at different sites.

KNOWN SIDE EFFECTS*

- Anaphylaxis, mild-to-moderate injection site reactions (erythema, pruritis, urticaria, hyperpigmentation at injection site), skeletal pain, pharyngitis, dyspnea and cough.
- In clinical trials of PBPC mobilization, 3% of patients experienced systemic allergic-like reactions, which resolved with administration of additional antihistamines and/or corticosteroids

SPECIAL PRECAUTIONS

- Store vials in refrigerator (2-8 degrees C)
- Any vials left at room temperature for more than 72 hours should be discarded.
- Absolute expiry of reconstituted vial = 24 hours in refrigerator
- Single use vial.
- Reconstitute each 1875 mcg vial with 1.2 mL SWFI to yield a final concentration of 1500 mcg/ml (1.5mg/ml). (Withdrawable volume = 1 ml)
- Premedications:
 1. H1 antagonist: eg. diphenhydramine 50 mg po q6h or cetirizine (not available at VGH) po 10 mg daily
 2. H2 antagonist eg. ranitidine 150 mg po bid
 3. Salbutamol inhaler 2 puffs 30-60 min pre-injection(Start H1 and H2 antagonists 12 to 24 hours prior to the first injection. Further administration should be timed such that a dose is given 60-90 minutes prior to each injection. Should continue until 48 hours after the last injection.

*** REPORT ANY ADVERSE DRUG REACTIONS TO THE PHARMACY**